Literature DB >> 17885298

Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine.

Tamara S Flys1, Anthony Mwatha, Laura A Guay, Clemensia Nakabiito, Deborah Donnell, Philippa Musoke, Francis Mmiro, J Brooks Jackson, Susan H Eshleman.   

Abstract

OBJECTIVES: Use of single dose nevirapine (SD NVP) for prevention of HIV-1 mother-to-child transmission (pMTCT) is associated with selection of K103N-containing HIV variants. Repeat use of SD NVP for pMTCT may influence emergence and persistence of NVP-resistant variants.
DESIGN: K103N-containing variants were studied in 48 Ugandan women who received SD NVP in the HIVNET 012 trial, and were re-exposed to SD NVP in one (n = 44) or two (n = 4) subsequent pregnancies during a 5-year follow-up study.
METHODS: Samples were analyzed using the LigAmp assay (assay cutoff: 0.5% K103N).
RESULTS: Among 44 women who were re-exposed to SD NVP in one subsequent pregnancy, 37.8% had K103N detected within 1 year of SD-NVP re-exposure. Detection of K103N was independently associated with detection of K103N 6-8 weeks after the first SD NVP exposure and with pre-NVP viral load. The portion of women with undetectable K103N by 2 years after SD NVP administration was similar after first versus second use of SD NVP for pMTCT. K103N was undetectable in 93.2% of evaluable women by 3 years of re-exposure. Only two of four women who received SD NVP in two pregnancies during the follow-up study had K103N detected after the last SD NVP exposure.
CONCLUSIONS: K103N was detected in some women within 1 year of SD NVP re-exposure, but faded from detection in most women by 3 years after re-exposure. Detection of K103N by 1 year after SD NVP re-exposure was associated with prior selection of K103N-containing variants and with pre-NVP viral load.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17885298     DOI: 10.1097/QAD.0b013e3282703847

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  10 in total

1.  HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.

Authors:  Gillian M Hunt; Ashraf Coovadia; Elaine J Abrams; Gayle Sherman; Tammy Meyers; Lynn Morris; Louise Kuhn
Journal:  AIDS       Date:  2011-07-31       Impact factor: 4.177

2.  Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.

Authors:  Mohammed Lamorde; Pauline Byakika-Kibwika; Violet Okaba-Kayom; John P Flaherty; Marta Boffito; Rhoda Namakula; Mairin Ryan; Clemensia Nakabiito; David J Back; Saye Khoo; Concepta Merry; Kimberly K Scarsi
Journal:  J Acquir Immune Defic Syndr       Date:  2010-11       Impact factor: 3.731

3.  Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa.

Authors:  Risa M Hoffman; Vivian Black; Karl Technau; Karin Joan van der Merwe; Judith Currier; Ashraf Coovadia; Matthew Chersich
Journal:  J Acquir Immune Defic Syndr       Date:  2010-05-01       Impact factor: 3.731

4.  Pregnancy does not affect HIV incidence test results obtained using the BED capture enzyme immunoassay or an antibody avidity assay.

Authors:  Oliver Laeyendecker; Jessica D Church; Amy E Oliver; Anthony Mwatha; S Michele Owen; Deborah Donnell; Ron Brookmeyer; Philippa Musoke; J Brooks Jackson; Laura Guay; Clemesia Nakabiito; Thomas C Quinn; Susan H Eshleman
Journal:  PLoS One       Date:  2010-10-11       Impact factor: 3.240

5.  Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission.

Authors:  Tamara S Flys; Michelle S McConnell; Flavia Matovu; Jessica D Church; Danstan Bagenda; Leila Khaki; Paul Bakaki; Michael C Thigpen; Chineta Eure; Mary Glenn Fowler; Susan H Eshleman
Journal:  J Infect Dis       Date:  2008-08-15       Impact factor: 5.226

Review 6.  Update on successes and challenges regarding mother-to-child transmission of HIV.

Authors:  Elijah Paintsil; Warren A Andiman
Journal:  Curr Opin Pediatr       Date:  2009-02       Impact factor: 2.856

7.  A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.

Authors:  Reshmi Samuel; Roger Paredes; Raveen Parboosing; Pravi Moodley; Lavanya Singh; Anneta Naidoo; Michelle Gordon
Journal:  J Med Virol       Date:  2015-05-04       Impact factor: 2.327

8.  HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission.

Authors:  Reshmi Samuel; Marc Noguera Julian; Roger Paredes; Raveen Parboosing; Pravi Moodley; Lavanya Singh; Anneta Naidoo; Michelle Gordon
Journal:  J Acquir Immune Defic Syndr       Date:  2016-12-01       Impact factor: 3.731

Review 9.  The challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART.

Authors:  Hakim Sendagire; Philippa J Easterbrook; Immaculate Nankya; Eric Arts; David Thomas; Steven J Reynolds
Journal:  AIDS Rev       Date:  2009 Apr-Jun       Impact factor: 2.500

10.  Frequency and factors associated with adherence to and completion of combination antiretroviral therapy for prevention of mother to child transmission in western Kenya.

Authors:  Paul Ayuo; Beverly Musick; Hai Liu; Paula Braitstein; Winstone Nyandiko; Boaz Otieno-Nyunya; Adrian Gardner; Kara Wools-Kaloustian
Journal:  J Int AIDS Soc       Date:  2013-01-02       Impact factor: 5.396

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.